about
Deep brain stimulation: are astrocytes a key driver behind the scene?Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists.The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease.Role of microglia adenosine A(2A) receptors in retinal and brain neurodegenerative diseases.Astrocytes and therapeutics for Parkinson's disease.Structure based prediction of subtype-selectivity for adenosine receptor antagonistsA randomized, double-blind, placebo-controlled study to investigate the safety, tolerability, and pharmacokinetics of single enantiomer (+)-mefloquine compared with racemic mefloquine in healthy persons3-(Fur-2-yl)-10-(2-phenylethyl)-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one, a novel adenosine receptor antagonist with A(2A)-mediated neuroprotective effects.Mucuna pruriens (Velvet bean) rescues motor, olfactory, mitochondrial and synaptic impairment in PINK1B9 Drosophila melanogaster genetic model of Parkinson's disease.Effects of coffee/caffeine on brain health and disease: What should I tell my patients?Mechanisms of the psychostimulant effects of caffeine: implications for substance use disorders.Pathophysiological roles for purines: adenosine, caffeine and urate.Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.From epidemiology to pathophysiology: what about caffeine in Alzheimer's disease?Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist.Effect of A(2A) receptor antagonist (SCH 442416) on the mRNA expression of glutamate aspartate transporter and glutamine synthetase in rat retinal Müller cells under hypoxic conditions in vitro.Optimization of adenosine 5'-carboxamide derivatives as adenosine receptor agonists using structure-based ligand design and fragment screening.Dopamine D(2) receptor-mediated modulation of adenosine A(2A) receptor agonist binding within the A(2A)R/D(2)R oligomer framework.Progress towards novel adenosine receptor therapeutics gleaned from the recent patent literature.The role of extracellular adenosine in chemical neurotransmission in the hippocampus and Basal Ganglia: pharmacological and clinical aspects.Adenosine A2A-receptor antagonism and pathophysiology of Parkinson's disease and drug-induced movement disorders.New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors.Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant.Molecular imaging of levodopa-induced dyskinesias.How does adenosine control neuronal dysfunction and neurodegeneration?Allosteric Communication Networks in Proteins Revealed through Pocket Crosstalk AnalysisAdenosine A(2A) Receptor Binding Profile of Two Antagonists, ST1535 and KW6002: Consideration on the Presence of Atypical Adenosine A(2A) Binding Sites.Investigation of the conformational dynamics of the apo A2A adenosine receptor.Istradefylline: first global approval.Mapping the allosteric sites of the A2A adenosine receptor.Preladenant, a selective adenosine A₂A receptor antagonist, is not associated with QT/QTc prolongation.Caffeine in Parkinson's disease: a pilot open-label, dose-escalation study.Essential Control of the Function of the Striatopallidal Neuron by Pre-coupled Complexes of Adenosine A2A-Dopamine D2 Receptor Heterotetramers and Adenylyl Cyclase.Treatment with Adenosine Receptor Agonist Ameliorates Pain Induced by Acute and Chronic Inflammation.Synthesis and Evaluation of Phenylxanthine Derivatives as Potential Dual A2AR Antagonists/MAO-B Inhibitors for Parkinson's Disease.
P2860
Q26830147-9659361C-3C4E-4002-8358-FCB2BA21ED62Q30435017-430150AE-09DC-4392-AF60-F9DC86946B93Q30458705-2392175F-56F9-424A-9200-E1958CFE48E1Q34014053-8AC19162-BBAA-47A4-8DD9-18E74F2F113BQ34168266-86250195-1218-462B-B746-69F6B8C1B776Q34306247-CC101C03-FBBC-42AC-9478-853A4A954BBAQ34341756-80D8F634-77BB-41CC-A201-3D99B6491804Q34365007-8C8B2756-FC73-4702-A388-6A1EF939B7C3Q34395518-F46D2986-CFBF-4D29-A5C1-1B155C682EADQ34505480-275DDC77-CFFE-4062-B650-BE3465AF4551Q34509861-8746210E-0B00-4C71-BBD9-85D22ECFE759Q35008049-EB1F0CF7-AA79-4726-A0FB-E5B1AC60D466Q35489240-26FC03D9-9CA0-42B2-9A9D-38A7951043BEQ35634105-11370B86-CC22-4821-8E70-B2D2A03AC1E5Q35738538-D9C3B24D-FC28-4101-9054-97EA0134BAACQ36224415-B251DD64-2FE3-47F9-A983-4202F11704BAQ36343219-B199CE3E-4588-4E2A-A97F-E8129AC66AF4Q36994873-1E871623-3050-4671-842A-91667D9D9C50Q37774652-41635A55-D2B3-47B3-8012-9497855A4A34Q37852727-C2B8266E-3B2F-43E0-9C47-4EB6633537BBQ37963718-F6C57C87-E5BF-44B2-A3DD-D15BB779ED31Q37974709-E6B439C5-0647-40A7-A2F2-EB2816A0D492Q37979869-109CED45-F4A4-4661-87AE-3D4EF5D5E8E2Q38199744-FC382990-A6A8-4B23-A19D-D6AFF7FB1DCEQ38355582-246E7C9D-545D-44FD-957B-491A72B4EED7Q38882782-C6EB7EBF-5989-4F33-BDD7-8763D366D457Q41815533-B29BB0B1-C57A-4620-A7D6-5611DCF7142FQ41849265-84869C2B-87A7-4BCA-8B3F-991702719878Q42563394-85F95391-A905-4AD7-8A42-ACCD68AB8C58Q44360692-E37D05CF-83A9-4F0C-9D17-B524CDDD0FEFQ46049863-35BED90F-A14C-4D3C-89C5-F94CF757461DQ46072562-6691C307-AC43-486F-A3F2-484FE81956DFQ50262567-9CA48218-0C98-461E-AAA5-E70CC32C12FAQ52311700-D91CD80D-CB4A-4FE0-AF30-AA181DC5D503Q53096946-670AD34A-92CD-4E54-B2D6-FA63B15282C9Q54013959-8E80E08D-3146-4CAB-A51B-1ACB629FBADC
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Adenosine A2A receptors and Parkinson's disease.
@en
Adenosine A2A receptors and Parkinson's disease.
@nl
type
label
Adenosine A2A receptors and Parkinson's disease.
@en
Adenosine A2A receptors and Parkinson's disease.
@nl
altLabel
Adenosine A2A Receptors and Parkinson’s Disease
@en
prefLabel
Adenosine A2A receptors and Parkinson's disease.
@en
Adenosine A2A receptors and Parkinson's disease.
@nl
P1476
Adenosine A2A receptors and Parkinson's disease
@en
P2093
Anna R Carta
Peter Jenner
P304
P356
10.1007/978-3-540-89615-9_18
P577
2009-01-01T00:00:00Z